Russell Peterson
Family Medicine · Roanoke, ALNPI 1144322504
Payments from drug & device makers
Across 143 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$817
- Novo Nordisk$803
- Lilly USA, LLC$391
- Boehringer Ingelheim$285
- GSK$183
- Shire North American Group Inc$49
- plus $215 from 10 others
What the payments were for
- Food & beverage$2,71799%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $817 |
| Novo Nordisk | 37 | $803 |
| Lilly USA, LLC | 24 | $391 |
| Boehringer Ingelheim | 24 | $285 |
| GSK | 9 | $183 |
| Shire North American Group Inc | 3 | $49 |
| Johnson & Johnson | 2 | $43 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Merck | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| AbbVie | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$237
- FASENRA$111
- TRELEGY ELLIPTA$103
How this compares
$2,743 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 561 | $107,961 |
| EnbrelEtanercept | 12 | $95,615 |
| XeljanzTofacitinib Citrate | 11 | $63,978 |
| OtezlaApremilast | 52 | $63,090 |
| MounjaroTirzepatide | 37 | $52,338 |
| TrulicityDulaglutide | 55 | $50,263 |
| FarxigaDapagliflozin Propanediol | 123 | $34,233 |
| RexultiBrexpiprazole | 45 | $31,549 |
| OzempicSemaglutide | 29 | $29,098 |
| NuedextaDextromethorphan Hbr/Quinidine | 46 | $26,247 |
| XareltoRivaroxaban | 65 | $22,390 |
| JardianceEmpagliflozin | 36 | $17,988 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,511 |
| Pantoprazole Sodium | 974 | $12,907 |
| MyrbetriqMirabegron | 60 | $11,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $391 | $102,60192 claims |
| AstraZenecaFarxiga | $817 | $34,233123 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $16 | $31,54945 claims |
| GSKTrelegy Ellipta, Arexvy, Incruse Ellipta | $183 | $29,61763 claims |
| Johnson & JohnsonXarelto, Invokana | $43 | $29,14677 claims |
| Novo NordiskOzempic | $803 | $29,09829 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $13 | $26,24746 claims |
| Boehringer IngelheimJardiance | $285 | $17,98836 claims |
| AbbVieCreon, Namzaric | $18 | $13,81437 claims |
| MerckJanuvia | $21 | $8,12653 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $24 | $7,12612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Roanoke
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.